Johnson & Johnson
(NYSE: JNJ)
+
announced it will invest more than $55 billion in its U.S. pharma and medtech operations over the next four years.
The investment is a 25% increase over its previous investment cycle. It bolsters the New Brunswick, N.J.-based company’s manufacturing, R&D and technology infrastructure. Johnson & Johnson said the investment is expected to deepen its economic footprint.
J&J made the announcement as it broke ground on a new $2 billion, 500,000 sq. ft biologics manufacturing facility in Wilson, N.C. The new site will support the production of next-generation treatments for cancer, autoimmune disorders, and neurological diseases.
“Today’s announcements accelerate our nearly 140-year legacy as an American innovation engine tackling the world’s toughest healthcare challenges,” CEO Joaquin Duato said in a…
